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Intracerebral hemorrhage (ICH) is a medical emergency, which often leads to severe dis-
ability and death. ICH-related poor outcomes are due to primary injury causing structural 
damage and mass effect and secondary injury in the perihemorrhagic region over several 
days to weeks. Secondary injury after ICH can be due to hematoma expansion (HE) or 
a consequence of repair pathway along the continuum of neuroinflammation, neuronal 
death, and perihemorrhagic edema (PHE). This review article is focused on PHE and 
HE and will cover the animal studies, related human studies, and clinical trials relating to 
these mechanisms of secondary brain injury in ICH patients.
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iNTRODUCTiON
Intracerebral hemorrhage (ICH) is a medical emergency, which often leads to severe disability and 
death (1). ICH-related poor outcome is due to the combined effect of primary injury and secondary 
injury. In the primary injury, the hematoma cleaves or dissects neuronal tissue over several hours 
leading to the presenting symptoms. The loss of neurons within the hematoma is extensive; although 
some islands of preserved neurons may exist (2). Hematoma expansion (HE) stops due to tamponade 
effect of the surrounding tissue or clotting at the parent vessel. Due to the rapid onset, the primary 
injury of ICH is difficult to treat. The best way to minimize the injury from primary insult would 
be the preventative measures in high-risk individuals and early access to care once symptoms start. 
Primary injury is followed by secondary injury in the perihemorrhagic region over several days to 
weeks and provides a longer treatment window than the primary injury. In survivors of ICH, the 
total extent of remodeled brain tissue may exceed the volume of the initial hematoma. This excess 
volume of remodeling serves as an evidence of secondary injury. There are multiple factors that 
contribute to secondary injury after ICH, some of which may occur concurrently or in sequence. 
Secondary injury after ICH can be separated into two major types: rebleeding causing HE and the 
consequences of repair pathways along the continuum of neuroinflammation and neuronal death, 
including perihemorrhagic edema (PHE), elevated intracranial pressure (ICP), hydrocephalus, and 
brain atrophy. This review article is focused on PHE and HE, and will cover the animal studies, 
related human studies, and the clinical trials relating to these mechanisms of secondary brain injury 
in ICH patients. Although numerous animal studies have shown promising targets for therapy to 
reduce PHE and HE, we currently do not have any approved therapy for either. Practice guidelines 
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published by the American Heart Association/American Stroke 
Association (AHA/ASA) in 2015 did not recommend any current 
therapy for PHE or HE (1).
PeRiHeMORRHAGiC eDeMA
Perihemorrhagic edema is often seen in ICH patients and 
causes mass effect on adjacent brain structures, elevation in 
ICP, hydrocephalus, or brain herniation often leading to clini-
cal deterioration. The extent of PHE after ICH is variable and is 
governed by several mechanisms including the early effects of 
the Starling oncotic forces and the late effects of cell breakdown, 
neuroinflammation, and disruption of the blood–brain barrier 
(BBB). The early PHE occurs without disruption of the BBB (3, 
4). PHE starts within 3 h of ICH onset and grows fastest in the 
first 3 days. PHE continues to grow for 7 days in rats (5) and for 
as long as 3 weeks in humans with peak between 2 and 3 weeks 
(4). Absolute PHE volume is linked to hematoma volume, low 
systolic blood pressure (BP), and high admission hematocrit 
(4). Admission partial thromboplastin time, baseline hematoma 
volume, history of hypertension, and earlier time from hematoma 
onset to CT are associated with higher relative PHE, defined as 
PHE per hematoma volume (4). PHE growth is associated with 
decline in neurological examination during hospitalization (6). 
Absolute, relative, and rate of increase in PHE are all related to 
death or dependency at 90 days (4, 7, 8). PHE-associated effect 
on clinical outcomes may be dependent on hematoma volume, as 
shown in three previous studies where PHE in setting of moder-
ate size hematoma volume around 30 cc was associated with poor 
outcomes (9–11). Hematoma location in basal ganglion was also 
found to be associated with an increase in PHE-related adverse 
outcomes (10). The formation of post-ICH brain edema is related 
to direct clot retraction releasing serum, which causes hydrostatic 
pressure leading to early edema in the first 72  h (12). Delayed 
edema is secondary to neuroinflammation and oxidative stress 
(13) from a cascade of reactions triggered by red blood cell lysis, 
thrombin production, complement activation, and neuroin-
flammation, which in turn causes damage to the BBB (14–16). 
NXY-059, a free radical scavenger, was studied in comparison 
to placebo in 607 patients and showed no benefit on HE, PHE, 
or clinical outcomes (17). The animal studies done so far have 
helped to delineate these mechanisms and provided some data 
for therapeutic targets.
Treatment of Perihemorrhagic edema
Targeting Direct Clot-Related Hydrostatic Pressure
Direct effect of clot-related hydrostatic pressure can be minimized 
using clot removal and/or osmotherapy. We present here the 
bench to bedside studies supporting each of these two treatment 
options.
Surgery
Animal magnetic resonance imaging (MRI) studies have found 
that PHE corresponds to reduced perfusion in the perihemor-
rhagic area (18, 19), but does not represent cytotoxic edema. 
Hematoma evacuation in study animals led to normalization 
of this reduced perfusion (18, 20). The non-cytotoxic nature 
of PHE is further supported by the lack of effect of reductions 
in BP and cerebral blood flow (CBF) on the extent of PHE 
in a study of ICH patients (21). Furthermore, PHE occurs 
in cadaveric models of ICH in the absence of any blood flow 
(22). Surgical removal of ICH hematoma improves CBF on the 
ipsilateral side as shown in a single-photon-emission computed 
tomography (SPECT) study (23). Based on supportive data 
from animal studies, the role of surgery in ICH was explored in 
humans. Unfortunately, two large multicenter surgical trials in 
ICH patients failed to show any benefit of surgery over medical 
therapy (24, 25). Mean time to surgery in these trials was more 
than 24  h, which may have affected the possible benefit from 
surgery in these studies. Data from rabbit studies suggest that 
early surgery within 6–12 h might be of maximum benefit with 
lower glutamate levels, less BBB permeability, and less brain 
edema (26). Since large studies did not find any role for open 
surgery in ICH management, the role of minimally invasive 
surgery is currently being explored. In a rat study, recombinant 
tissue plasminogen activator (rt-PA) was found to be safe after 
ICH (27). In a phase-II ICH trial investigating hematoma 
evacuation using minimally invasive surgery and intra-lesional 
rt-PA (MISTIE-II), there was significant reduction in PHE in 
the minimally invasive surgical group with no ill effects of rt-PA 
(28). MISTIE-III trial is in underway to investigate the effect 
of hematoma reduction using minimally invasive surgery and 
intra-lesional rt-PA on long-term patient outcomes. MISTIE-III 
promises to be an important ICH trial and will further improve 
our understanding about ICH management (29). Large volume 
hematoma and PHE may lead to severe mass effect including 
uncal herniation and death. Decompressive hemicraniectomy is 
sometimes used in clinical practice as a life saving measure. In 
a retrospective case series, clot evacuation with decompressive 
hemicraniectomy for large ICH was associated with a favorable 
outcome in 29% patients (30). Decompressive hemicraniec-
tomy trials with (31) and without (32) hematoma evacuation 
are currently enrolling patients to study the effect of surgery 
versus medical therapy in ICH patients. Although animal stud-
ies suggest reduced CBF in the perihemorrhagic region with 
improvement following surgery, the role of surgery still needs to 
be established in humans. Currently, the AHA/ASA guidelines 
do not recommend surgery for all ICH patients. The guidelines 
do recommend urgent sub-occipital craniectomy for cerebellar 
ICH patients with neurological decline, brainstem compression, 
or obstructive hydrocephalus (1).
Hyperosmolar Therapy
Mannitol is a commonly used osmotherapy agent for cerebral 
edema. The effect of mannitol on ICH-related edema and patient 
outcome is controversial. In rat studies, mannitol did not cause 
any change in the brain water content suggesting lack of its effect 
in ICH-related edema (33). However, a transcranial Doppler 
study showed that a single bolus of 100  mg mannitol in ICH 
patients led to higher mean flow velocity and lower pulsatility 
index suggesting reduced edema on the affected side (34). In two 
studies, mannitol was found to be safe in ICH patients, although 
had no clinical response (35, 36). However, Sansing et al. showed 
that mannitol had no effect on PHE but was related to adverse 
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discharge outcome (37). Although one study showed transient 
clinical improvement with mannitol, it failed to show any 
improvement on computed tomography (CT) (38). A systematic 
review reported only two small trials about the use of mannitol 
in ICH and concluded that there was not enough evidence to 
suggest either benefit or harm with mannitol (39).
Hypertonic saline is another common mode of osmotherapy 
for PHE. In an ICH dog study, basal ganglia ICH was related 
to higher perilesional pressures, and administration of 23.4% 
hypertonic saline bolus led to reduction in intraparenchymal 
pressure; this effect was sustained for 3 h (40). An experimental 
dog study of ICH-induced transtentorial herniation found eleva-
tion in ICP with preservation of cerebral perfusion pressure due 
to concomitant arterial hypertension. Transtentorial herniation 
was accompanied by reduction in regional CBF in brainstem 
and bilateral gray/white matter. A bolus of 23.4% hypertonic 
saline reversed the effect of transtentorial herniation on ICP and 
restored CBF and cerebral oxygen consumption. The reduction 
in ICP after a single hypertonic saline bolus lasted 30 min (41). 
In a retrospective study of herniating ICH patients, two-thirds of 
the patients had reversal of herniation after a bolus of 30–60 ml 
of 23.4% hypertonic saline (42). Herniation reversal is associated 
with a good functional outcome in 25% patients (43). In two ret-
rospective studies of 78 ICH patients and 132 historical controls, 
continuous 3% saline infusion with goal serum sodium concen-
tration of 145–155  mmol/l and osmolality of 310–320  mOsm/
kg led to less PHE on day 14, less ICP elevation, and reduced 
mortality with similar safety profile (cardiac arrhythmias, acute 
heart failure, pulmonary edema, and acute renal failure) (44). 
Another retrospective study also failed to show any higher risk 
of acute kidney injury with the use of hypertonic saline in ICH 
patients (45).
The effectiveness of hypertonic saline in reducing ICP and 
reversing herniation syndromes has been compared to the effec-
tiveness of mannitol. In an experimental dog study with ICH in 
left basal ganglia, use of hypertonic saline [3% NaCl (5.3 ml/kg) 
or 23.4% NaCl (0.7 ml/kg)] caused reduction in ICP immediately 
and at 15 min. Mannitol (1 gm/kg) led to an immediate reduction 
in ICP, but this effect did not persist at 15 min. Only 3% NaCl 
caused a persistent reduction in ICP at 120 min (46). In humans, 
20% ICH patients did not respond adequately (change in sodium 
≤5 mEq/l) to sustained mannitol infusion (47). Although animal 
studies and retrospective studies suggest benefit of hyperosmolar 
therapy in reversing transtentorial herniation and reducing ICP, 
this effect needs to be proved in RCTs.
Targeting ICH-Related Neuroinflammation and 
Oxidative Stress
Numerous animal studies have investigated the effect of clot 
lysis and the cascade of reactions that follow. The result of this 
cascade is neuroinflammation and the consequent late stages of 
PHE (48). We present here a few animal studies and correspond-
ing human studies, which have investigated some of the targets 
to reduce neuroinflammation-induced PHE. Hemoglobin 
released from hematoma lysis leads to iron deposition, gluta-
mate deposition (49), free radical production, and antioxidase 
deactivation causing activation of matrix metalloproteinases-9 
(MMP-9). MMP-9 plays an important role in BBB disruption, 
PHE, apoptosis, and neuronal death. Inflammation involving 
microglia activation and leukocyte infiltrations; and possible 
mitochondrial dysfunction also contribute to this oxidative 
stress (13). However, the role of BBB disruption in the forma-
tion of PHE has not been clearly defined in human studies. BBB 
disruption has been disputed as a cause of PHE by at least one 
group of authors (50). If BBB disruption does contribute to 
perihematomal edema formation, it is most likely a late effect. 
MMP-9 has been found to be elevated in ICH patients and is 
associated with HE and clinical decline (51, 52).
Hypothermia
Hypothermia was noted to be effective for treating brain edema 
and BBB disruption in animal studies. It involves upregulation 
of tight junction proteins and the suppression of inflammatory 
cytokines [interleukin 1β (IL-1β) and tumor necrosis factor α 
(TNF-α)] (53, 54). Hypothermia further reduces the expression 
of MMP-9 and apoptosis (55). In addition, elevated ambient 
temperature has deleterious effect on PHE. Elevated ambient 
temperature in patients in intensive BP reduction in acute cer-
ebral hemorrhage trial (INTERACT) was found to be associated 
with worsening PHE (56) consistent with prior animal studies 
(57, 58). A meta-analysis of animal studies found hypothermia to 
be ineffective in reducing brain edema (48) contrary to a human 
study of ICH patients (12 experimental versus 25 control) where 
hypothermia up to 35°C showed more reduction in edema in the 
experimental group (59). A phase-II hypothermia trial in ICH 
is exploring role of hypothermia (32–34°C) in improving edema 
and patient outcomes (60). Although there is conflicting data in 
the animal studies, the role of hypothermia in reducing the PHE 
or improving patient outcomes warrants future studies.
Iron Chelators
Hemoglobin degradation leading to iron deposition contributes 
to PHE. In animal models, heme diffused rapidly through 
perivascular spaces and induced heme oxygenase-1 enzyme that 
led to accumulation of ferritin and hemosiderin; generation of 
free radicals; neuronal injury; and BBB disruption (61). In a 
rat study, ferrous iron was found to cause brain injury, making 
this a potential target for chelation therapy (62). Lipocalin-2, a 
siderophore-binding protein, present in astrocytes, microglia, 
neurons, and endothelial cells, is involved in cellular iron trans-
port and neuroinflammation. Lipocalin-2 plays an active role in 
iron toxicity after ICH with ferritin upregulation in ipsilateral 
basal ganglia, microglial activation, more brain swelling, brain 
atrophy, and neurological deficits (63). In ICH rat studies, brain 
pathology showed iron overload and upregulation of iron-
handling proteins (transferrin, transferrin receptor, and ferritin) 
(64). In human studies of ICH patients, high serum ferritin 
(65–67), low serum iron, and low transferrin were correlated 
with high hematoma volume, early PHE, and poor outcome at 
90 days (68). Another study suggested that the effect of ferritin 
on poor clinical outcomes is not a direct cause and effect but a 
marker of iron-related PHE, which in turn causes a direct effect 
on patient outcomes (69). In an MRI study in ICH patients, 
increased iron deposition in the hematoma and the contralateral 
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globus pallidus was associated with increased PHE suggesting 
iron overload in the brain may contribute to PHE (70).
In rat and piglet studies, deferoxamine, an iron chelator, 
reduced ferritin upregulation, hematoma lysis, hematoma cav-
ity size, neuronal death, and neurological deficits (71–74). The 
iron chelator enters the perifocal reactive zone via the disrupted 
BBB (61). A phase-I study of 20 patients found deferoxamine 
(7–62 mg/kg/day) to be safe in ICH patients (75). A controlled 
study of 42 patients showed slowing of hematoma absorption 
and reduction in PHE using deferoxamine without any clini-
cal benefit (76). Currently, two controlled trials are ongoing to 
study the effect of deferoxamine on PHE and long-term clinical 
outcomes (77, 78).
Minocycline is another iron chelator, MMP-9 inhibitor, 
and anti-inflammatory drug, which has reduced iron-related 
neuronal injury in animals along with reducing PHE, neuronal 
death, improving BBB, and improving neurobehavioral outcomes 
(79–83). A combined phase-I and phase-II study is currently 
recruiting 24 ICH patients to test the safety and pharmacokinet-
ics of minocycline and to simultaneously test its effect on blood 
biomarkers (84). Animal and early human studies support a 
toxic role of iron in ICH-related neuroinflammation and oxida-
tive damage. Ongoing clinical trials will explore the role of iron 
chelation on PHE and patient outcomes.
Statins
Statins are inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme-
A (HMG-CoA) reductase and are commonly used medications 
for dyslipidemia. In animal studies, statins showed less neuronal 
tissue loss and inflammation; increased cell proliferation, angio-
genesis, and synaptogenesis in the perihemorrhagic zone with 
better functional outcomes (85–87). Statins’ neuroprotective 
actions may be explained by their ability to induce expression of 
vascular endothelial growth factor (VEGF), brain-derived neu-
rotrophic factor (BDNF), and nerve growth factor (NGF) (88) to 
reduce activated microglia, MMP-9 (89), and cytokine-mediated 
inflammation (less TNF-α and higher interleukin-10 levels) (90, 
91). Statins also reduce BBB dysfunction, edema, tissue loss, and 
improve CBF in the perihemorrhagic zone (92, 93). Combination 
of granulocyte-colony stimulating factor (G-CSF) and statins 
further enhance their neuroprotective capacity with less cell 
apoptosis than with either agents alone (94). Combination of 
statins and deferoxamine showed a greater effect on PHE and 
hematoma volume than either agent alone (95). Unlike animal 
studies, statin use in humans has been linked to increased PHE 
volume in ICH patients with no effect on CBF (96). One study of 
303 ICH patients with 71 statin users showed higher initial and 
final hematoma volume in statin users (97). Conversely, a pilot 
study of 18 patients showed a possible protective role of rosuvas-
tatin in ICH patients with lower mortality; however, after adjust-
ment for disease severity, the hazards ratio was not significant 
(HR 0.20; 95% CI 0.02–1.67) (98). A meta-analysis of 17 studies 
with 3455 ICH patients exposed to statins showed a significant 
risk reduction of mortality (OR 0.73; 95% CI 0.54–0.97) (99). 
Three studies assessed the effect of statin discontinuation follow-
ing ICH and noted a trend toward reduction in mortality risk 
with continuation of statins (OR 0.14; 95% CI 0.1–0.20) (99–102). 
Animal studies suggesting a beneficial role of statins in reducing 
neuroinflammation and retrospective human studies showing 
conflicting results set the stage for a large phase-III trial to explore 
the potential benefit of continuing statins in ICH patients who 
were receiving statins prior to ICH onset.
Memantine
Animal studies demonstrate that elevated glutamate after ICH 
contributes to BBB breakdown, neuronal death, and brain edema 
via stimulating N-methyl-d-aspartate (NMDA) receptors (49). 
A meta-analysis of animal studies did not show any benefit of 
glutamate receptor antagonists (Amantadine, Memantine, and 
YM872) on PHE (48). However, the effect of memantine has 
been consistently positive. Memantine, an FDA-approved 
NMDA antagonist for Alzheimer’s disease, showed benefit for 
ICH in animal studies with reduced hematoma growth, reduced 
inflammation with low MMP-9 level, less apoptosis, and bet-
ter functional recovery (103). A similar effect was seen along 
with reduced PHE in another study with the combination of 
memantine and celecoxib, a selective cyclooxygenase-2 (COX-2) 
inhibitor. The effect of this combination on PHE was better than 
the use of single agent (104). A single-centered RCT of 64 ICH 
patients confirmed the beneficial effect of memantine with better 
modified Rankin score and Barthel index at 90 days (105). With 
supportive data from animal studies and a single-centered RCT 
in humans, there is enough preliminary data to support a large 
multicenter RCT to confirm these findings. There are currently 
no registered trials looking at role of memantine in ICH.
Celecoxib
Animal models with ICH have shown that celecoxib, a selective 
cyclooxygenase-2 (COX-2) inhibitor, has anti-inflammatory, 
antioxidant, and neuroprotective effects. Celecoxib use was 
associated with reduced brain edema, prostaglandin E2 level, 
perihematomal cell death, and better neurobehavioral recovery 
(106). As mentioned earlier, celecoxib in combination with 
memantine was associated with less apoptosis, less inflammation, 
reduced hematoma volume and brain edema, and better func-
tional recovery. The effect was greater than each drug alone (104). 
In a retrospective study of ICH patients, celecoxib (400 mg/day) 
for ≥7 days significantly reduced the hematoma volume and PHE 
as compared to controls, without any difference in adverse events 
(107). These findings were further confirmed in multicenter RCT 
of 44 ICH patients where celecoxib 400 mg twice a day was given 
for 14 days (108). To confirm the findings of animal studies and 
a single small RCT, a larger trial is needed to show the effect of 
celecoxib on clinical outcomes in ICH patients.
Fingolimod
Animal studies showed that PHE results from inflammatory 
response with perilesional infiltration of neutrophils and mac-
rophages, activation of microglia, ICAM-1 immunoreactivity, 
and leakage of BBB (109, 110). A sphingosine-1-phosphate 
receptor (S1PR) modulator, fingolimod was found to have mixed 
results in animal studies varying from no effect on PHE or clinical 
outcomes (111) to reduced edema with better neurobehavioral 
recovery (112–114). The positive effect from fingolimod is 
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due to reduction in lymphocytes, markers of inflammation 
[intercellular adhesion molecule-1 (ICAM-1), interferon-γ, and 
interleukin-17], apoptosis, and brain atrophy (112–114). In a 
human study of 23 patients, fingolimod use was associated with 
less inflammation (reduced ICAM-1, lymphocytes, natural killer 
cells, and MMP-9 levels) and positive effect on BBB (115). In 
a phase-II study, fingolimod use within 72 h of ICH onset was 
associated with less PHE and improvement in clinical outcomes 
at 3 months without any increase in side effects (116). Fingolimod 
use is limited due to its potential for cardiotoxicity. RP101075, a 
selective S1PR1 agonist, has less potential for cardiotoxicity, yet, 
it retains the ability to reduce cerebral edema in mice. RP101075 
results in less cytokine expression, higher BBB integrity, less 
infiltration of lymphocytes, neutrophils, and microglia, and less 
cell death (117). Human studies with RP101075 are awaited. 
Although animal studies and a phase-II human study suggest a 
possible beneficial role of fingolimod, a phase-III study is needed 
to confirm these findings.
Hyperglycemia
A rat study has shown that induced hyperglycemia leads to more 
cell death in perihemorrhagic region and more global edema 
(118). Another animal study found a correlation between perile-
sional hyperglycemia and PHE and suggested a possible role for 
hyperglycemia in BBB breakdown (119). A post hoc exploratory 
analysis of the antihypertensive treatment of acute cerebral hem-
orrhage (ATACH) trial found a trend toward worsening of PHE 
with hyperglycemia, but it was not statistically significant (rela-
tive risk 1.25; CI 0.73–2.13) (120). Another retrospective study 
did not find any relationship between hyperglycemia and PHE 
in ICH patients (121). Supporting data from animal studies and 
conflicting results from two small human studies point toward 
need for more data to understand role of hyperglycemia on PHE 
in ICH patients before future trials can be planned. AHA/ASA 
guidelines recommend avoiding hypoglycemia or hyperglycemia 
in ICH patients (1).
Current AHA/ASA guidelines do not recommend routine use 
of any anti-inflammatory agents in ICH patients (1).
HeMATOMA eXPANSiON
About one-third of the ICH patients have HE within 3  h and 
one-sixth in the first 6 h causing early neurological decline and 
increasing the risk of long-term poor outcomes (1, 122). HE may 
be related to prior antithrombotic use, computed tomography 
angiography (CTA) spot sign (123), heterogeneous hematoma 
density, irregular hematoma shape (124), platelet dysfunction, 
and higher BP (1). Currently, there are no approved therapies for 
reducing HE. We will discuss some potential methods of reducing 
HE for which we have basic science research, or clinical evidence, 
regarding their potential application at the bedside.
Treatment of Hematoma expansion
Activated Recombinant Factor VII
An animal study found hematoma reduction in experimental 
ICH rats with use of activated recombinant factor VII (rFVIIa) 
(125). In humans, an open-label uncontrolled study found 
benefit of rFVIIa in controlling ICH in patients with hemophilia 
A or B (126). The benefit of rFVIIa in hemophilia triggered inter-
est for its use in ICH patients without hemophilia and a phase-II 
safety study of 48 patients found it to be safe with adverse events 
(rash, vomiting, fever, ECG T-wave inversion, and deep venous 
thrombosis) in 12.5% patients (122). This safety study led to a 
RCT of 399 patients, which found reduction in hematoma vol-
ume with rFVIIa as compared to placebo (11–16 versus 29%). 
Hematoma growth was reduced by 3–6  ml depending on the 
rFVIIa dose (40–160 μg/kg). Poor outcome including mortality 
was reduced at 90 days, despite rFVIIa-related serious adverse 
events in 2.3% patients (myocardial or cerebral infarction) 
(127). A follow-up efficacy study of 841 patients again showed 
reduction in HE with rFVIIa as compared to placebo (11–18 
versus 26%). However, in this larger study, there was an excess 
in arterial thrombotic events and there was no overall clinical 
benefit, while the trend was toward greater death and disability 
in the treatment group with rFVIIa as compared to placebo 
(26–29 versus 24%) (128).
Few studies have explored the potential benefit of rFVIIa dur-
ing the perioperative management for ICH patients. Use of rFVIIa 
(40–90 μg/kg) prior to hematoma evacuation in 15 patients with 
mean preoperative ICH volume of 60 ml was found to be safe 
with good outcome in 73% patients (129). In another placebo-
controlled open-label study, rFVIIa was used during hematoma 
evacuation (100  μg/kg) with no difference in postoperative 
hematoma volume and adverse events (130). It remains to be seen 
how rFVIIa would find a place in ICH management knowing that 
animal and phase-III studies have shown that it reduces HE. The 
clinical benefit would have to outweigh the side effect of arterial 
thrombosis and the right dose and clinical setting would need 
to be narrowly defined. Currently, AHA/ASA and neurocritical 
care society (NCS) guidelines recommend against use of rFVIIa 
in ICH patients (1, 131).
Warfarin Reversal
Oral anticoagulation (OAC) is a common risk factor for ICH 
associated with higher rate of HE and poor clinical outcomes. 
In a rat study, higher INR was associated with higher hematoma 
volume. OAC-related hematoma enlargement occurred in the 
first 3 h of ICH onset (132). Interestingly, warfarin also reduced 
the cell death and MMP-9 levels; however, HE was out of pro-
portion than this positive effect (133). Warfarin-related HE has 
been confirmed in several human studies (134–137). Following 
warfarin-related ICH, warfarin is held and emergent reversal of 
the warfarin effect is needed. A meta-analysis comparing agents: 
prothrombin complex concentrate (PCC) and fresh frozen 
plasma (FFP) for warfarin reversal included five RCTs and eight 
observational studies. PCC use was associated with significant 
normalization of INR, shorter time to INR correction, lower risk 
of posttransfusion volume overload, and less mortality without 
any added risk of thromboembolism (138). A RCT of PCC 
versus FFP in ICH patients is currently recruiting patients (139). 
Supporting animal studies and phase-III studies have led to NCS 
recommendations of administering PCC with intravenous vita-
min K over FFP and vitamin K combination for warfarin reversal 
for ICH patients (131).
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Newer Anticoagulants Reversal
In large RCTs of anticoagulation after atrial fibrillation, direct 
thrombin inhibitors (dabigatran) and direct factor Xa inhibitors 
(apixaban, rivaroxaban) were associated with lower annual rate 
of hemorrhagic stroke when compared to warfarin (140), which 
made them the agents of choice for secondary stroke preven-
tion in atrial fibrillation patients. Their main limiting factor was 
non-availability of a reversal agent in case of hemorrhage. There 
was uncertainty around the effect of these medications on ICH 
volume. An animal study using dabigatran etexilate did not find 
any significant change in ICH volume when compared to placebo 
(141). In humans, most cases of newer anticoagulants (NOAC)-
related ICH has reported hematoma size less than 30  cc with 
very low risk for HE (136, 142–144). Need for reversal agents for 
these agents led to research on Idarucizumab, an antibody frag-
ment, which is currently food and drug administration (FDA) 
approved. It was studied in 90 patients (51 patients with acute 
serious bleeding) taking dabigatran and was found to normalize 
the abnormal thrombin and ecarin clotting time in more than 
80% patients within minutes resulting in normal hemostasis 
within 11.4 h. There were 5.6% patients with thrombotic events 
over the next 30 days (145). In a rat study, Idarucizumab was 
associated with reduced mortality (146). Andexanet  alfa, a 
recombinant modified human factor Xa decoy protein, was 
evaluated in 67 patients with acute major gastrointestinal or 
intracranial bleeding while on factor Xa inhibitor. Anti-factor 
Xa activity decreased consistently for 2  h by more than 80% 
from baseline. Clinical hemostasis was achieved in 79% patients 
within 12 h; however, there were 18% patients with thrombotic 
events during the 30-day follow-up (147). Andexanet alfa is not 
yet approved by FDA. Future trials may help us understand if 
this change in hemostasis using these novel medications will 
translate into better clinical outcome.
Another important issue in ICH patients requiring antico-
agulation for atrial fibrillation or mechanical heart valve is the 
timing of resumption of anticoagulation after ICH. There is no 
previous RCT answering this question and a phase-II study is 
currently recruiting patients to compare the safety of apixaban 
versus antiplatelet agents or no antiplatelet/anticoagulation agent 
in atrial fibrillation patients after ICH (148). Current NCS guide-
lines recommend using activated charcoal and PCC if needed for 
direct factor Xa inhibitor-related ICH. They recommend use of 
Idarucizumab for dabigatran-related ICH, which is supported by 
animal and current human studies (131).
Antiplatelet Reversal
Elderly patients with ICH are often taking antiplatelet agents 
prior to admission. An experimental rat study did not find any 
significant change in hematoma volume or neurological deficits 
between rats that were pretreated with antiplatelet agent before 
ICH versus those who were not pretreated (149). However, in 
humans, prior antiplatelet agent use has been associated with 
higher risk of HE and poor outcome, with aspirin having the 
lowest risk as compared to clopidogrel or ticlopidine (135, 150). 
In a pilot study of 14 ICH patients, desmopressin use was found 
to be safe and resulted in improvement of platelet function war-
ranting larger studies to confirm these findings (151). A recently 
completed European randomized, open-label, and phase-III trial 
studying platelet transfusion versus standard care after acute ICH 
with prior antiplatelet therapy (PATCH) found two times higher 
odds of death or dependence at 3 months in patients receiving 
platelet transfusion (152). It remains to be seen if findings from 
the PATCH trial will be validated in another blinded RCT in a 
continent other than Europe. A larger RCT is awaited to study 
the efficacy of desmopressin on ICH patient outcomes. Despite 
conflicting data from the animal study and early human studies, 
current NCS guidelines recommend using a dose of desmopres-
sin (0.4 mcg/kg IV) in ICH patients on antiplatelet agents prior 
to admission and platelet transfusion only in patients scheduled 
to undergo neurosurgery (131).
BP Reduction
Hypertension is common in ICH patients with two-thirds of 
patients having systolic BP more than 140 mm Hg at presentation 
(153). A rat study found acute BP elevation in either normotensive 
or hypertensive rats after ICH, which is associated with higher 
HE, more brain swelling, and worse neurological deficits (154, 
155). Since acute ICH leads to activation of the adrenergic system, 
the role of antiadrenergic agents needs to be explored. There are 
conflicting data about the effect of beta-blockade on clinical 
outcomes following ICH. Inpatient use of antiadrenergic medica-
tions (beta-blockers or clonidine) in 303 patients was associated 
with less PHE and better clinical outcome after controlling for 
hematoma volume and BP (156). This protective effect of anti-
adrenergic medications was confirmed by another study of 138 
ICH patients where in-hospital atenolol use was associated with 
less mortality, systemic inflammatory response, and pneumonia 
(157). This protective effect of antiadrenergic medications was 
challenged by a large cohort study from Denmark with 11,779 
ICH patients who showed no benefit of preadmission beta 
blockers over long-term mortality (158). A US study of 426 ICH 
patients did not find any class-specific benefit of beta-blockers 
over other antihypertensives (159).
Another area of interest in ICH is intense BP control defined 
as less than 140/90 mm Hg. ATACH-II, a recent RCT studying 
role of intensive BP control versus standard BP management 
in ICH patients found a trend toward less HE (≥33%) in the 
intensive BP arm (18.9 versus 24.4%, p = 0.09) (160). Another 
similar trial also showed a trend toward less absolute hematoma 
volume change in the intensive arm as compared to standard BP 
management (3.1 versus 4.9 ml, p = 0.09) (161). However, both 
these trials failed to show any benefit in clinical outcomes with 
intensive BP control. A pooled analysis of five RCTs also showed 
no benefit of aggressive BP lowering on patient outcomes or HE 
(162). A new open-label, dose-escalating study of glyceryl trini-
trate transdermal patch in ICH patients is underway, to study the 
effect of BP control in the first 2 h of symptom onset by starting 
medication via the emergency medical services (163). Although 
animal studies suggested possible role of BP control in reducing 
HE in ICH patients, failed phase-III RCTs do not support it. There 
is probably some role of BP control on HE; however, the right BP 
target and timing to achieve it needs further evaluation. AHA/
ASA guidelines suggest that acute systolic BP lowering to 140 mm 
Hg is safe and can be effective for improving functional outcomes 
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(1). It remains to be seen if these guidelines would change after 
the recently published ATACH II trial.
Tranexamic Acid
Tranexamic acid is an antifibrinolytic agent, which acts by inhib-
iting conversion of plasminogen to plasmin. In an experimental 
rat ICH study, combination of plasminogen and thrombin was 
noted to cause significant neuronal damage, which was prevented 
by tranexamic acid (164). A RCT including 30 ICH patients 
found that tranexamic acid group had no significant hematoma 
growth as compared to control (165). Another pilot study showed 
that two patients per month can be enrolled to study the effect 
of tranexamic acid on ICH patients (166). Animal studies and 
positive pilot studies support the ongoing two phase-II studies to 
explore the benefit of tranexamic acid for ICH patients (167, 168). 
Lack of strong evidence explains why tranexamic acid is missing 
in the current ICH guidelines from AHA/ASA (1).
Memantine
In addition to its possible benefit in reducing PHE, memantine 
has been purported to have some role in preventing HE. In a rat 
study, memantine use was associated with reduction in tissue 
plasminogen activator (tPA), urokinase plasminogen activator 
(uPA), MMP-9, and HE (103). In a study of 186 ICH patients, 
elevated MMP-9 was independently associated with the risk of 
HE (OR 15.65, 95% CI: 5.30–46.15) (52). Another rat study with 
a combination therapy with memantine and celecoxib showed a 
reduction in cerebral inflammation, apoptosis, hematoma vol-
ume, and better functional recovery (104). A single-centered RCT 
of 64 ICH patients confirmed the beneficial effect to memantine 
in humans on outcomes, but they did not study its effect on HE 
(105). The effect of memantine on HE and clinical outcomes in 
animals would need further evidence in humans to achieve clini-
cal utility. There are currently no registered trials looking at the 
role of memantine in ICH; memantine is not listed in the current 
AHA/ASA guidelines (1).
Hyperglycemia
A rat study found that hyperglycemia via its interaction with 
plasma kallikrein, leads to HE via inhibition of collagen-induced 
platelet aggregation (169). Another animal study found protective 
role of 17-beta estradiol in preventing hyperglycemia-induced 
harmful effect on HE. A post hoc exploratory analysis of ATACH 
trial found a statistically significant worsening of HE with hyper-
glycemia (120). Hyperglycemia associated HE worsening was 
also seen in another retrospective study, but the association was 
not statistically significant (121). Prospective cohort studies are 
needed to understand the association between hypoglycemia and 
HE. As mentioned previously, AHA/ASA guidelines recommend 
avoiding hypoglycemia or hyperglycemia in ICH patients (1).
CONCLUSiON
Despite extensive animal data supporting numerous therapeutic 
targets to prevent morbidity and mortality in ICH, very few 
studies have made the journey from bench to bedside. Failures 
of recent ICH trials have given us an opportunity to rethink 
the paradigms of the management for ICH patients. What are 
the critical steps in improving the outcomes of these patients? 
Is early hematoma evacuation using minimally invasive sur-
gery crucial to minimizing injury by preventing the cascade 
of secondary injury? Is the need for critical care (reversal of 
antiplatelet agents and anticoagulation agents, BP control, 
hyperglycemia control, cerebral edema management, venous 
thromboembolism prevention) the key to prevention of second-
ary injury? Is it the use of anti-inflammatory agents like statins 
and Fingolimod? Or is there some other, yet undetermined, 
factor? An MRI animal study suggests that mortality may be 
determined less by hematoma volume than by the invasion of 
internal capsule suggesting an anatomically more eloquent basis 
for clinical deterioration (170). Patient selection may be the key 
as not everyone would benefit from either surgery or medical 
therapy, possibly depending on damage to an eloquent area or 
pathway during the primary injury.
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